Terutroban

Terutroban

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Investigational
Pharmacokinetic data
Biological half-life	6–10 hours
Identifiers
IUPAC name 3-((6R)-6-{[(4-Chlorophenyl)sulfonyl]amido}-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoic acid
CAS Number	165538-40-9 N
PubChem CID	9938840
ChemSpider	8114465 N
UNII	A6WX9391D8
ECHA InfoCard	100.107.361
Chemical and physical data
Formula	C20H22ClNO4S
Molar mass	407.911 g/mol
3D model (Jmol)	Interactive image
SMILES CC1=C(C2=C(CC(CC2)NS(=O)(=O)C3=CC=C(C=C3)Cl)C=C1)CCC(=O)O
InChI InChI=1S/C20H22ClNO4S/c1-13-2-3-14-12-16(6-9-19(14)18(13)10-11-20(23)24)22-27(25,26)17-7-4-15(21)5-8-17/h2-5,7-8,16,22H,6,9-12H2,1H3,(H,23,24)/t16-/m1/s1 N Key:HWEOXFSBSQIWSY-MRXNPFEDSA-N N
NY (what is this?)

Terutroban is an antiplatelet agent developed by Servier Laboratories. It has been tested for the secondary prevention of acute thrombotic complications in the Phase III clinical trial PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack). The study was prematurely stopped and thus it could not be determined whether terutroban has a better effect than aspirin.

Terutroban is a selective antagonist of the thromboxane receptor. It blocks thromboxane induced platelet aggregation and vasoconstriction.